Fluid and Imaging Biomarkers in Neuroscience Summit on October 07-09, 2025 in Boston, United States

As the only industry-driven forum focused exclusively on biomarker discovery and validation for neurodegenerative and neuroinflammatory diseases, the 3rd Fluid and Imaging Biomarkers in Neuroscience Summit unites biotech, pharma and academic scientists to transform diagnosis and monitoring of Alzheimer's, Parkinson's, ALS, and MS.

Join 80+ experts from Roche, Prothena, Eisai, Michael J. Fox Foundation and more to decode regulatory pathways, optimize IND timing, and harness breakthrough insights in p-tau217, alpha-synuclein, emerging omics platforms, and more.

As the field rapidly shifts toward blood-based diagnostics, high-sensitivity assays, and regulatory clarity, this is your unparalleled opportunity to collaborate with CNS biomarker leaders to shape a new wave of omics-based discoveries, surrogate endpoint success stories, pre-symptomatic detection technologies, and more.

URLs:

Tickets: https://go.evvnt.com/3137146-2?pid=10008

Brochure: https://go.evvnt.com/3137146-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 3497.00,

Academic Pricing - 3 Day Pass (Conference + Workshop Day): USD 2897.00,

Vendor Pricing - 3 Day Pass (Conference + Workshop Day): USD 5097.00,

Drug Developer Pricing - Conference Only: USD 2599.00,

Academic Pricing - Conference Only: USD 2199.00,

Vendor Pricing - Conference Only: USD 3699.00

Speakers: Andrei Popescu, Neuroscience Biomarker Lead in Translational Molecular Biomarkers, Merck, Anna Moore, Principal Scientist in Biomarkers and Pharmacology , PTC Therapeutics, Antonio Chambers, Director, Eli Lilly, Charlotte Chung, Director of Research, Voyager Therapeutics, Elizabeth Evans, Chief Operating Officer, Vaccinex, Fernanda Cerqueira, Senior Associate Director, Michael J. Fox Foundation, Holly Soares, Global Head of Neuroscience and Rare Disease Biomarkers, Vice President, Roche, Indu Navar, Chief Executive Officer and Founder, EverythingALS, Jiri Aubrecht, Vice President and Head of Clinical Biomarkers, Prothena, Jon Levenson, Chief Scientific Officer, FireCyte Pharmaceuticals, Laura Rosen, Senior Vice President, Acumen Pharmaceuticals, Leslie Shaw, Professor, Biomarker Research, University of Pennsylvania, Mihaly Hajos. Chief Scientific Officer, Cognito Therapeutics, Mike Baratta, Senior Director, Head of Mass Spectrometry-Clinical Bioanalysis, Takeda, Nadine Tatton, Executive Director, Critical Path Institute, Pablo Vaccari, Associate Professor, University of Miami, Miller School of Medicine, Pallavi Sachdev, Executive Director, Head of Translational Medicine, Eisai, Stephen Zicha, Senior Director, Eli Lilly, Terina Martinez, Executive Director, Critical Path Institute